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Summary 
Affinity chromatography and reverse-phase high-performance liquid chromatography was used 
to purify a soluble interleukin lfl (Ib13) specific binding protein from the supernatant of a human 
B cell line, Raji.  The purified protein specifically bound 12sI IL-lfl forming a 60-kD complex 
in nonreducing conditions and a 70-kD complex in reducing conditions. Binding was found 
to be displaceable by mature human and murine IL-lfl and human 31-kD ILlfl propeptide, but 
not displaceable by human and murine II.-loe or human Ibl receptor (ID1R) antagonist. Ligand 
blotting revealed a 47-kD molecule that spedfically bound IL-lfl. Measurement of binding affinity 
of the call surface Raji IL-1R  (Ka  =  2.2 nm) and the Raji soluble (s)IL-1R  (Ka  =  2.7 rim) 
demonstrated a similar affinity for 12sI ILlfl. Purified sIblR inhibited binding of IL-lfl to cell 
lines with both type I (80 kD) and type II (65 kD) IblRs,  but did not interfere with Iblc~ 
binding. This natural slblR may function as an important regulatory molecule of IL-lfl in vivo. 
I  blc~ and IL-lfl are polypeptides with central roles in the 
regulation of immune and inflammatory reactions (1). ILl 
responses are mediated by specific high affinity cell surface 
receptors (II~IR) of which at least two distinct forms are 
known to exist (2). An 80-kD (type I) receptor is found mainly 
on T  cells and fibroblasts (3), and a lower molecular mass 
65-kD, (type II) receptor is found on B cells (4) and macro- 
phages. Many cytokine receptors are known to exist in soluble 
form, and release from the cell surface occurs by two distinct 
mechanisms. Alternative splicing of the primary RNA tran- 
script can result in protein isoforms that lack transmembrane 
domains and are therefore secreted, e.g., IL-4R (5). Proteolytic 
cleavage of the transmembrane molecule at the cell surface, 
e.g., IL2R (p55) (6), also results in receptor shedding. Other 
cytokine receptors that exist in soluble form include those 
for IL-2 (p75) IL-5, II~6, IL-7, IFN-'y, TNF (p75 and p55), 
epidermal growth factor (EGF),  and M-CSF. 
We have recently described a sohble binding protein specific 
for IL-lfl present in normal human plasma (7), serum, syno- 
vial inflammatory exudate, activated PBMC supernatants (8), 
and supernatants from the human B cell line, Raji (9). Stim- 
ulation of Raji with dexamethasone increased surface expres- 
sion of the ID1R and the rate of release of soluble binding 
protein. Conversely, a serine protease inhibitor prevented re- 
lease of the binding protein and increased IL-1R expression 
of the cells. Together, the data indicate that the soluble IL-lfl 
binding protein is probably a proteolyticaUy cleaved form of 
a surface IL1R. Here we report the purification and charac- 
terization of this novel soluble (s)IL-1R and provide evidence 
that it may function as a naturally occurring regadator of IL-lfl. 
Materials and Methods 
Purification  ofRaji slL.1g.  The Raji cell line was obtained from 
the European Cell Culture Collection (Porton, Wilts, UK). Ceils 
were maintained at 37~  in RPMI 1640 containing 5% FCS, and 
media was aspirated every 3-4 d, centrifuged, and stored at -50~ 
Before purification, cukure supernatants were concentrated 20-fold 
using a Minitan ultra filtration system containing  10-kD cut-off 
filters (MiUipore  Continental Water Systems, Bedford, MA). slblR 
protein was detected by soluble covalent crosslinking as previously 
described (8). 
Partial purification of the sIblR was achieved using a wheat- 
germ agglutinin sepharose  6MB column (Pharmacia  LKB Biotech- 
nology, UK) as previously described, sIblR was further purified 
using a IL-lfl (mutant K138C) (10) thiol sepharose column con- 
taining 4 mg/ml Iblfl. Concentrated Iblfl binding protein prepa- 
rations were applied to the column using a flow rate of 1 ml/min 
and continually recycled for up to 48 h at 4~  The column was 
then washed in 100 mM Tris-HC1, pH 8.1 (20-column volumes), 
100 mM Tris-HC1, pH 8.1, 1.0 M NaC1 (20-column volumes), and 
subsequently eluted with 5 ml of 3 M  NH4SCN  in PBS. The 
eluate was extensively  dialyzed against 100 mM Tris-HC1, pH 8.1, 
concentrated 10-fold with a centripep concentrator (cut-off, 10 kD; 
Amicon Ltd.) and stored at  -70~ 
Affinity-purified,  sIL-1R,  was injected onto a reverse-phase,  RP300 
Aquapore  30 x 2.1-mm C8 column (Applied  Biosystems  Inc., Foster 
City, CA). Sample was eluted in a 10-70%  (vol/vol) acetonitrile 
gradient with 0.3%  (vol/vol) trifluoroacetic acid over a 45-min 
period at a flow rate of 0.2 ml/min. After neutralization with Tris, 
fractions were screened for IL-1 binding activity by soluble cova- 
lent crosslinking. 
Ligand Blotting ofslL-1g.  Purified sIL-1R. (5/zl) was subjected 
to electrophoresis on 10%  SDS-polyacrylamide gels and trans- 
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Raji  slL-1R  with  12Sl Ib.l~. 
Purified slL-1R was subjected  to 
electrophoresis  on  a  10%  SDS 
polyacrylamide gel and transfer~ 
onto  0.45-/~M  nitrocellulose 
filters. After blocking, filters were 
probed with 12sI IL-I~ (5 ng/ml) 
alone (lane I), with excess I1r 
(lane 2), with excess IblB (lane 
3), and with excess TNFc~ (lane 
4).  Protein markers are in kilo- 
daltons. 
Figure 1.  Specificity of ligand binding of the slblR.. Purified slL-1R 
was incubated with 12sI IL-1B in the absence or presence  of a 500-fold 
excess cold cytokine. After crosslinking and SDS-PAGE, complexes were 
identified by autoradiography. Lane I, no competing agent (nonreducing 
conditions); lane 2, excess murine Ibla; lane 3, excess murine IL-1B; lane 
4, excess human IL-la; lane 5, excess human IblB; lane 6, excess human 
IL-I~ propeptide; lane 7, excess human I1r  antagonist; lane 8, excess 
TNF-oq lane 9, no competing agent (reducing conditions). Protein markers 
are in kilodahons. 
ferred electrophoretically to 0.45-#m nitrocellulose filters (Biorad, 
Herts, UK). Ligand blotting was then performed as previously de- 
scribed (11). 
Soluble and Cell Su~ce 12s111,1  Binding  Assay.  Soluble  binding 
assays with purified slL-1R and cell surface binding  assays using 
5  x  106 cells were performed as previously described (8). 
Inhibition of Cell Surface  11,1 Binding by slL1R.  Raji and Eb4 
NOB.1 cells (107) were incubated with 5 ng/ml 12sI Iblc~ or 12sI 
IL-lfl with or without decreasing concentrations of purified sIb 
1R at 4~  for 3 h with constant agitation.  Cell surface 12sI Ibl 
binding was assessed as before. 
Results 
Purification ofRaji slL-IR.  Wheat germ agglutinin and 
Ibl/~  affinity-purified, soluble  II.-1R  was  injected onto  a 
reverse-phase  HPLC  column,  sIL-1R  eluted  with  ~43% 
(vol/vol) acetonitrile as determined by soluble crosslinking 
and was associated with three overlapping protein peaks (data 
not  shown). 
Specificity of  slL,1R Ligand Binding.  The specificity of the 
Raji slL-1R was investigated by adding a 500-fold excess of 
cold cytokine to purified slL-1R incubated with 125I Ib13. 
The results shown in Fig. I show a 60-kD complex that was 
formed between 12si IIA3 and the purified slblR in the ab- 
sence of a competing agent (lane 1). Addition of excess human 
Iblo~ (lane 2) or murine Ibloe (lane 4) did not inhibit binding, 
however, addition of excess human ILIB (lane 3) or murine 
II.-1/3 (lane 5) displaced 125I IL-13 binding,  as did the addi- 
tion of 500-fold excess human 31-kD Ib13 (lane 6).  Excess 
TNF-o~ (lane 8) or human rlblR antagonist (lane 7) did not 
inhibit  125I I1.-1/3 binding.  Lane  9  shows  the  effect  of 
reducing conditions on the apparent molecular mass of the 
12sI II.-I~/AIIclR complex,  reduction of disulphide bonds 
causing the complex to migrate at  •69  kD. 
Ligand Blotting of slL-13 Binding Protein.  Purified slblR 
was separated on a 10% SDS-PAGE  gel under nonreducing 
conditions and blotted onto nitrocellulose. Probing with 12sI 
IL-13 revealed a band migrating at 47 kD (Fig. 2). This band 
was also seen when the blots were incubated with 100-fold 
excess cold ILlot or TNF-ot but not when incubated with 
excess cold II:1/3. No binding was seen when the slL-1R was 
separated under reducing conditions (data not shown). 
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Figure 3.  Specific binding of cell surface and soluble Raji IL-1R. Reji cells (,t) or purified Raji slL-1R (/3) were incubated with varying concentrations 
of 12sI Ibl~ for 4 h at 8~  and ligand-receptor complexes separated from flee ligand by centrifugation through phthalate oil mixture (/1) or by pt~'ipi- 
tation with polyethylene glycol (B). Binding shown represents  specific binding Scatchard analysis (inset)  gives Kd of (A) ",2.2 nM and (B) '~2.7 nM. 
Results are representative of two experiments. 
1252  Characterization of a Natural Soluble Interleukin 1 Receptor Cell Surface and Soluble Raft II~IR Binding.  Analysis of 
12sI I1:1/5 binding to the Raji cell surface IL-1K and sllclK 
showed that both exhibited specific  and saturable binding (Fig. 
3). Scatchard analysis revealed that the Raji cell surface I1:1K 
bound lz5I I1:1/5 with an apparent Kd of 2.2 nM (Fig. 3 A), 
while the soluble receptor protein bound 12sI I1:1/5 with a 
Ka of 2.7 nM (Fig. 3 B). 
Inhibition of lLIR Binding by slIMR.  Raji (type II I1:1R 
bearing) and EL-4 NOB.1 (type I IL-1K bearing) cells were 
incubated with nsI I1:1ot and nsI I1:1/5 in the presence or 
absence of decreasing concentrations of purified sI1:lR (Fig. 
4). Raji did not bind 12sI I1:1c~ (data not shown), however, 
nsI IL-1/5 binding was inhibited in a dose-related fashion by 
the sI1:lK preparation.  The sI1:lR also inhibited nsI I1:1/5 
binding to  the E1:4 NOB.1  cell line,  however,  nsI I1:1c~ 
binding was not affected by incubation with sI1:lR. 
Discussion 
The present  study described the purification  and charac- 
terization of a sIL-1R derived from the supernatant  of the 
human B cell Burkitt lymphoma cell line Raft. The protein 
binds Ibl/5 but not Iblo~.  We have previously described a 
protein with the same properties in normal human plasma, 
serum, synovial exudate,  and supernatants  from activated 
PBMC (7,  8). 
We purified the Raji sI1:lR by sequential wheat germ ag- 
glutinin affinity chromatography, Ibl/5 affinity chromatog- 
raphy, and reverse-phase HPLC. The specificity of this mate- 
rial was characterized by using soluble covalent crosslinking 
and confirmed our previous findings that the sILLR specificaUy 
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Figure 4.  Inhibition  of cell surface IL.1R binding by sIL-1R. Raji and 
EL-4 NOB.1 cells (10  ~) were incubated with 5 ng/ml lzsI IL-1 in the pres- 
ence of various concentrations of purified sIL-1R.. After incubation  at 8~ 
for 4 h, bound and free ligand were separated by centrifugation through 
a phtalate oil mixture. Binding in the absence of slL-1R was 6,852 cpm 
for IL-lol and Eb4, 4,339 cpm for IL-1B, and EL-4 and 3,052 cpm for 
IL-1B and Raji. Results are representative of three individual  e~periments. 
bound to IL-1/5. Murine IL-1 molecules  showed the same 
binding specifidty to the purified slL-1R. The human IblR 
antagonist (12) failed to inhibit binding of lzsI IL-1/5 to the 
slI~lR, and it has been reported that this molecule fails to 
bind the type II cell surface I1:IR. Interestingly,  we found 
that excess human 31-kD IL-1/5 propeptide could displace the 
mature 17-kD molecule from the sIDIR. Previously published 
studies have shown that the IL-1B propeptide fails to bind 
the type I I1:1R and has no biological activity on cells with 
this receptor (13). The finding that the sIblR binds to the 
propeptide may have important implications for the in vivo 
handiing of Ibl/5. Treatment of the sIL-1R/nSI I1:1/5 com- 
plex with reducing agents revealed an apparent change in the 
molecular mass of the complex from ,,060 to '~70 kD. As 
I1:1/5 contains no disulphide linkages, it is likely that the sIL-1R 
is held in its conformational shape by disulphide  bonds. 
Further characterization of the sIblR was achieved  by ligand 
blotting, previously used to study a number of cell surface 
receptors, including the type I IblR (11). Ligand blotting 
demonstrated a 47-kD molecule in nonreducing conditions 
that, again, specifically  bound Ibl/5. Use of reducing agents 
led to loss of binding activity (data not shown), indicating 
that the disulphide-bonded cysteine residues probably hold 
the receptor in a functional conformation. 
Scatchard analysis of cell surface and soluble  l~sI IL1/5 
binding showed the Ka of the cell surface IblR to be 2.2 
riM. This is in good agreement with previous studies (14). 
We have previously demonstrated that a sIbl/5 binding pro- 
tein semi-purified from synovial fluid (SF) had a Ka of *0.4 
nM (8). Analysis of the binding of IL-1/5 to the Raji sIblR 
revealed a Kd of 2.7 nM very similar to the Raji cell surface 
IblR, although others have found Raji sI1:lR to have a lower 
affinity (15). The sixfold difference in the affinity of the SF 
sI1:lR and the Raji-derived  sI1:lR might be explained by 
other Ibl binding factors in the SF preparations.  However, 
pancreatic islet/5 cells also possess I1:IR specific for Ibl/5 
and appear to express both high (Kd  =  0.2 riM) and low 
(Ka =  1.4 nM) sites (16), therefore synovial cells may shed 
a higher affinity sIblR than the Raji done. 
Given the high affinity for ILd/5, the molecule may func- 
tion as a specific inhibitor of I1:1/5 in vivo. To test this, we 
performed binding studies using EL-4 NOB.l, a T cell line 
with a type I IblR, and Raji cells that only possess a type 
II ID1R. The results showed that the sIblR inhibited IL-1/5 
binding to both cell lines in a dose-dependent fashion, how- 
ever, Iblot binding to E1:4 NOB.1 was not inhibited. Soluble 
cytokine receptors may have considerable therapeutic poten- 
tial. Recent studies have used a recombinant truncated type 
I I1:IR to inhibit rejection of heart aUografts (17) and I1:1 
induced B cell function (18). The natural soluble IL1R may 
play an important role in modulating I1:1/5 activities in vivo. 
The finding of certain cell types able to discriminate be- 
tween IL-lc~  and I1:1/5 has important biological implications. 
It has been noted that I1:1/5 is more potent than Iblol in 
the brain, pancreas, ovarian granulosa cells, leydig cells, and 
immunostimulatory activity in vivo. Differential expression 
of IL-1R types may explain these observations. Additionally 
release of the sI1:lR could be induced from normal human 
1253  Symons et al.  Brief Definitive Report PBMC after stimulation with mitogen (8), indicating that 
this IL-1/~-specific  IblR probably plays a role in normal im- 
mune  responses.  The  natural  slL-1R  may  be  useful  in 
modulating the actions of IL-I~ in vivo, especially where im- 
munopathogenesis is associated  specifically with Ibl~. 
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